S'abonner

Chronic obstructive pulmonary disease in the adult population within the Middle East and North Africa region: rationale and design of the BREATHE study - 04/01/13

Doi : 10.1016/S0954-6111(12)70010-0 
Abdelkader El Hasnaoui a, , Nauman Rashid a, Aicha Lahlou b, Hocine Salhi c, Adam Doble c, Chakib Nejjari d

on behalf of the BREATHE Study Group*

  BREATHE Steering Committee members (in alphabetical order of names): Ashraf Alzaabi, Zayed Military Hospital, Abu Dhabi, UAE; Majed Beji, La Rabta Hospital, Tunis, Tunisia; Ali Ben Kheder, Abderrahmane Mami Hospital, Tunis, Tunisia; Magdi Idrees, Riyadh Military Hospital, Riyadh, Saudi Arabia; Ghali Iraqui, Moulay Youssef Hospital, Rabat, Morocco; Arshad Javaid, Lady Reading Hospital, Peshawar, Pakistan; Javaid Ahmed Khan, Aga Khan University Hospital, Karachi, Pakistan; Adel Khattab, Ain Shams University, Cairo, Egypt; Marie Louise Koniski, Lebanese American University, Beirut, Lebanon; Bassam Mahboub, University of Sharjah, Sharjah, UAE; Salim Nafti, Mustapha Bacha Hospital, Algiers, Algeria; Nathir M. Obeidat, University of Jordan, Amman, Jordan; Mehmet Polatli, Adnan Menderes University, Aydin, Turkey; Abdullah Sayiner, Ege University, Izmir, Turkey; Naem Shahrour, Alasaad University Hospital, Damascus, Syria; Mohamed Awad Tageldin, Ain Shams University, Cairo, Egypt; Samya Taright, Bab-El-Oued Hospital, Algiers, Algeria; Esra Uzaslan, Uludag University Medical Faculty, Bursa, Turkey; Seraj Wali, King Abdulaziz University, Jeddah, Saudi Arabia.

a GlaxoSmithKline, Dubai, UAE 
b MS Health, Rabat, Morocco 
c Foxymed, Paris, France 
d Epidemiology Department, University of Fez, Fez, Morocco 

* Corresponding author. Dr Abdelkader El Hasnaoui, GlaxoSmithKline, PO Box 50199, Dubai, United Arab Emirates. Tel.: +971 4409 6305; fax: +971 4332 3071

Summary

The objective of the BREATHE study was to estimate the regional prevalence of chronic obstructive pulmonary disease (COPD) symptoms within the general population in the Middle East/North Africa (MENA) region and to document risk factors, disease characteristics and management using a standardised methodology.

This was an observational population-based survey performed in ten countries in the Middle East and North Africa (Algeria, Egypt, Jordan, Lebanon, Morocco, Saudi Arabia, Syria, Tunisia, Turkey and United Arab Emirates), together with Pakistan. A general population sample of 10,000 subjects ≥40 years of age in each country or zone was generated from random telephone numbers. Structured interviews were proposed by telephone. A screening questionnaire was administered to each subject collecting information on respiratory symptoms and smoking habits. Subjects with chronic bronchitis or breathlessness and smoking ≥10 pack·years fulfilled the epidemiological definition of COPD (“COPD” population). This population then completed a full disease questionnaire, the COPD Assessment Test (CAT) and a cost-of-disease questionnaire. A randomly selected sample was also assessed by spirometry. In all, 457,258 telephone numbers were generated and contact was established with 210,121 subjects, of whom 65,154 were eligible and 62,086 accepted to participate. The overall response rate was 74.2%. 2,187 (3.5%) subjects fulfilled the criteria for the “COPD” population. Evaluable spirometry data were obtained from 1,847 (14.2%) subjects to whom it was proposed.

The BREATHE study has collected a large amount of information on COPD variables from a representative sample of the general population of countries in the MENA region, which can be compared with other regional COPD initiatives.

Le texte complet de cet article est disponible en PDF.

Keywords : COPD, Middle East, North Africa, BREATHE study, Epidemiology, Prevalence, Smoking


Plan


 BREATHE core team members: Abdelkader El Hasnaoui, GlaxoSmithKline, Dubai, UAE; Nauman Rashid, GlaxoSmithKline, Dubai, UAE; Aïcha Lahlou, MS Health, Rabat, Morocco; Adam Doble, Foxymed, Paris, France, Hocine Salhi, Foxymed, Paris, France and Chakib Nejjari Faculty of Medicine of Fez, Fez, Morocco.
Conflict of interest statement
AEH and NR are employees of GlaxoSmithKline Laboratories, which funded the BREATHE study and market a number of treatments for COPD. AL is a director of MS Health, the clinical and epidemiological research company responsible for implementation of the study, collection of the data and statistical analysis of the results of the BREATHE study on behalf of GlaxoSmithKline Laboratories. HS and AD are employees of Foxymed, a medical communication and consultancy company which participated in the exploration and interpretation of the results of the BREATHE study on behalf of GlaxoSmithKline Laboratories and prepared the manuscripts for publication. CN advised on the data management and statistical analysis of the results of the BREATHE study on behalf of GlaxoSmithKline Laboratories.


© 2012  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 106 - N° S2

P. S3-S15 - décembre 2012 Retour au numéro
Article précédent Article précédent
  • Guest Editorial
  • Nicola A. Hanania
| Article suivant Article suivant
  • Smoking habits in the Middle East and North Africa: Results of the BREATHE study
  • Adel Khattab, Arshad Javaid, Ghali Iraqi, Ashraf Alzaabi, Ali Ben Kheder, Marie-Louise Koniski, Naem Shahrour, Samya Taright, Magdy Idrees, Mehmet Polatli, Nauman Rashid, Abdelkader El Hasnaoui, on behalf of the BREATHE Study Group B

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.